Related Experiment Video
Updated: Jun 19, 2026

Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a
Xiaojing Yang1, Min Feng, Xia Jiang
1Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672.
Abstract:
The Rb-E2F pathway drives cell cycle progression and cell proliferation, and the molecular strategies safeguarding its activity are not fully understood. Here we report that E2F1 directly transactivates miR-449a/b. miR-449a/b targets and inhibits oncogenic CDK6 and CDC25A, resulting in pRb dephosphorylation and cell cycle arrest at G1 phase, revealing a negative feedback regulation of the pRb-E2F1 pathway. Moreover, miR-449a/b expression in cancer cells is epigenetically repressed through histone H3 Lys27 trimethylation, and epigenetic drug treatment targeting histone methylation results in strong induction of miR-449a/b. Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer.
Insights
The Rb-E2F pathway is regulated by miR-449a/b, which inhibits cell proliferation. Epigenetic repression of miR-449a/b in cancer allows uncontrolled cell growth, highlighting its tumor suppressor role.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Biology
Background:
- The Retinoblastoma (Rb)-E2F pathway is crucial for cell cycle progression and proliferation.
- Mechanisms maintaining Rb-E2F pathway activity are not fully elucidated.
- Dysregulation of this pathway is implicated in human cancers.
Purpose of the Study:
- To investigate the regulatory role of microRNAs in the Rb-E2F pathway.
- To identify novel feedback mechanisms controlling cell cycle progression.
- To explore the epigenetic regulation of microRNAs in cancer.
Main Methods:
- Luciferase reporter assays to confirm E2F1-mediated transactivation of miR-449a/b.
- Western blotting to assess protein levels of CDK6, CDC25A, and phosphorylated Rb.
- Quantitative PCR to measure miR-449a/b expression.
- Chromatin immunoprecipitation assays to analyze histone modifications.
- Treatment of cancer cells with epigenetic drugs targeting histone methylation.
Main Results:
- E2F1 directly activates the transcription of miR-449a/b.
- miR-449a/b targets and inhibits oncogenic CDK6 and CDC25A.
- This inhibition leads to pRb dephosphorylation and G1 cell cycle arrest, establishing negative feedback.
- miR-449a/b expression is epigenetically silenced in cancer cells via H3K27 trimethylation.
- Epigenetic drug treatment restores miR-449a/b expression and inhibits cell proliferation.
Conclusions:
- miR-449a/b acts as a tumor suppressor by negatively regulating the Rb/E2F1 pathway.
- Aberrant epigenetic silencing of miR-449a/b contributes to E2F1 deregulation in cancer.
- Targeting epigenetic mechanisms offers a potential therapeutic strategy for cancers with deregulated E2F1 activity.
Related Concept Videos
Negative Regulator Molecules
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Mitogens and the Cell Cycle
Cell Specific Gene Expression
Abnormal Proliferation

